|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate : 52-week results from an open-label extension of the J-RAPID study
This item is licensed under:Creative Commons Attribution 3.0 Unported
| Title: | Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate : 52-week results from an open-label extension of the J-RAPID study |
| Authors: | Tanaka, Yoshiya Browse this author →KAKEN DB | | Yamamoto, Kazuhiko Browse this author →KAKEN DB | | Takeuchi, Tsutomu Browse this author →KAKEN DB | | Yamanaka, Hisashi Browse this author →KAKEN DB | | Ishiguro, Naoki Browse this author →KAKEN DB | | Eguchi, Katsumi Browse this author →KAKEN DB | | Watanabe, Akira Browse this author →KAKEN DB | | Origasa, Hideki Browse this author →KAKEN DB | | Shoji, Toshiharu Browse this author | | Miyasaka, Nobuyuki Browse this author →KAKEN DB | | Koike, Takao Browse this author →KAKEN DB |
| Keywords: | Certolizumab pegol | | Clinical study | | Rheumatoid arthritis | | TNF α | | TNF inhibitor |
| Issue Date: | 2014 |
| Publisher: | Informa Healthcare |
| Journal Title: | Modern Rheumatology |
| Volume: | 24 |
| Issue: | 5 |
| Start Page: | 734 |
| End Page: | 743 |
| Publisher DOI: | 10.3109/14397595.2014.881709 |
| Abstract: | Objectives. To evaluate the long-term efficacy and safety of certolizumab pegol (CZP) plus methotrexate treatment and to assess the efficacy of two CZP maintenance dosing schedules in Japanese rheumatoid arthritis (RA) patients with an inadequate response to methotrexate. Methods. J-RAPID double-blind patients were entered into an open-label extension (OLE) study. Patients withdrawn due to lack of efficacy at 16 weeks and double-blind completers without a week-24 American College of Rheumatology (ACR) 20 response received CZP 200 mg every other week (Q2W) plus methotrexate. Double-blind completers with week-24 ACR20 responses were randomized to CZP 200 mg Q2W plus methotrexate or CZP 400 mg every 4 weeks plus methotrexate. Results. The ACR20/ACR50/ACR70 response rates of double-blind completers (n = 204) were 89.7%/67.2%/36.3% at OLE entry and 95.6%/84.8%/58.3% at 52 weeks, respectively. Other clinical, functional and radiographic outcomes were sustained with long-term CZP plus methotrexate. Long-term treatment with CZP was well-tolerated with no new unexpected adverse events observed. The efficacy and safety of CZP treatment were similar between the two dosing schedules. Conclusions. Continued CZP administration with methotrexate maintained efficacy over 52 weeks and was well-tolerated for Japanese RA patients. No obvious differences in clinical efficacy and safety were observed between the two dosing schedules, giving flexibility in maintenance administration schedules. |
| Rights: | http://creativecommons.org/licenses/by/3.0 |
| Type: | article |
| URI: | http://hdl.handle.net/2115/62843 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 小池 隆夫
|
